Label Image For 500mg (Levetiracetam 500mg)
Levetiracetam
Product Images NDC 53808-0636
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 53808-0636). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label Image For 750mg (Levetiracetam 750mg)
Figure 1 (Levetiracetam Fig1)
The text appears to be a part of a figure caption containing information about the responder rate reduction in Study 1. A graph shows the percentage reduction in responder rate from the baseline. The treatment with Levetiracetam at a dose of 1000 mg/day and 2000 mg/day is compared to placebo, and the figure indicates the percentage of patients falling under each category. The text denotes the percentage reduction of 396% from the baseline. The information in the text is insufficient to provide a complete understanding of the context.*
Figure 2 (Levetiracetam Fig2)
Figure 2 shows the responder rate in Study 2 for patients treated with either Levetiracetam or placebo, with a 250% reduction from baseline. The graph displays the percentage of patients achieving the responder rate at different doses of Levetiracetam (100mg/day and 2000 mg/day) and a placebo group. The study found that Levetiracetam was statistically significant compared to the placebo.*
Figure 3 (Levetiracetam Fig3)
The text describes Figure 3 of a study. The figure shows the responder rate in Study 3 (-50% reduction from baseline) and the percentages of patients who responded to a placebo and a medication called Lewtiracstn. The medication was given at a dose of 5mg/day and the patients who received it had a statistically significant improvement compared to the placebo group.*
Figure 4 (Levetiracetam Fig4)
The figure shows the responder rate, which is the percentage of participants who achieved more than 50% reduction from baseline in their condition. The results suggest that the treatment (B) had a responder rate of 44.6%, which was statistically significant compared to placebo (10.6%). There were 97 participants in the placebo group.*
Figure 5 (Levetiracetam Fig5)
The image shows the responder rate in PGTC seizure frequency, with a 250% reduction from baseline per week. The graph includes results for patients taking placebo (N=84) and levetiracetam (N=79) and highlights a statistically significant difference between the two groups. No other information is available.*
Chemical Structure (Levetiracetam Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
